dichlorphenamide
Commercial- Indications
- Primary Periodic Paralysis
Company intelligence / Profile preview
Strongbridge Biopharma
Trevose, Pennsylvania, United Statesxerispharma.com ↗
- Ownership
- Public · SBBP
- Employees
- ~65
- Development stage
- Commercial
01
Overview
Strongbridge commercialized KEVEYIS® (dichlorphenamide) for primary periodic paralysis and advanced RECORLEV® (levoketoconazole) for endogenous Cushing’s syndrome through successful Phase 3 trials and NDA submission. Recorlev showed normalization of cortisol in ~30% of patients after six months in pivotal studies. Veldoreotide was in preclinical/early clinical development for acromegaly[8].
- Therapeutic areas
- EndocrinologyCardiovascularRare Diseases
- Modalities
- Small moleculessynthetic peptides[6]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Strongbridge Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Strongbridge Biopharma.